TAT-PiET, a cell-penetrating peptide, targets the extra-terminal (ET) domain of BRD4, disrupting the critical BRD4/JMJD6 protein complex interaction necessary for oncogene expression in breast cancer. By inhibiting BRD4/JMJD6 target gene expression, TAT-PiET effectively suppresses breast cancer cell growth and confers resistance to endocrine therapy in ERalpha-positive breast cancer cells, marking it as a potential inhibitor of breast cancer.
Molecular Weight:
2651.07
CAS Number:
[3036046-03-1]
Formula:
C110H192N48O27S
Target:
Epigenetic Reader Domain
TP2673
TP2673
* VAT and and shipping costs not included. Errors and price changes excepted
